Trial Profile
A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Betamethasone dipropionate (Primary) ; Corticosteroid
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Sponsors Primus Pharmaceuticals; Promius Pharma
- 05 Mar 2020 Status changed from recruiting to discontinued.
- 14 Feb 2018 Planned number of patients changed from 75 to 50.
- 14 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.